인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록·키워드
Critical-sized bone defects (CSBDs) are causing a significant challenge in orthopedic surgery for their inability to heal spontaneously, demanding innovative biomaterials to enhance bone formation. Current therapies, as autografts and allografts, are restricted by donor site morbidity and immune rejection. The current study presents a novel, biocompatible composite material formed of nano-graphene oxide (nGO), mineral trioxide aggregate (MTA), and hydroxyapatite (HAp) and designed to synergistically control the unique characters of each component. The novelty of this composite is due to its composition as it formed via the combination of nGO for enhancement of the mechanical strength and the cell proliferation, MTA for its higher bioactivity and its ability for cement formation, while the HAp having optimum biocompatibility and osteoconductivity, this synergistic interaction was not previously explored for CSBD repair. The current study utilized a rat model of critical-sized radial bone defects. The nGO/MTA/HAp composite was manufactured by consuming a modified Hummer’s method for nGO, combined with commercially available MTA and HAp. Radiographic and computed tomography (CT) evaluation at 2-, 4-, and 8-weeks post-operation elaborating the progressive bone formation in the treated group compared to minimal changes in the untreated group. Histopathological examination demonstrated strong composite integration, massive cellular infiltration, and strong signs of osteoblast differentiation, causing approximately 75–85% defect closure at the 8th week. The current study highlights the potential of the nGO/MTA/HAp composite as a biocompatible and osteoinductive composite for CSBD repair, presenting enhanced mechanical strength, bioactivity, and osteoconductivity.
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
최근 본 자료 전체보기
